Frontotemporal Dementia (FTD) Investment Landscape

Investment Landscape: Frontotemporal Dementia

Overview

Investment Landscape: Frontotemporal Dementia covers the current R&D investment,
clinical trial pipeline, and funding trends for Frontotemporal Dementia research.

Last updated: 2026-03-22 03:00 PT

Clinical Trial Pipeline

Total Clinical Trials: 380 Active Trials (Recruiting/Active): 124

Trial Phases

| Phase | Count |
|-------|-------|
| PHASE1 | 34 |
| PHASE1, PHASE2 | 12 |
| PHASE2 | 46 |
| PHASE2, PHASE3 | 3 |
| PHASE3 | 12 |
| PHASE4 | 8 |
| NA | 111 |
| Not Applicable | 144 |

Trial Status

| Status | Count |
|--------|-------|
| RECRUITING | 84 |
| ACTIVE_NOT_RECRUITING | 24 |
| NOT_YET_RECRUITING | 16 |
| COMPLETED | 172 |
| TERMINATED | 19 |
| WITHDRAWN | 10 |

Top Therapeutic Approaches

• genetic: 71 trials
• mitochondrial: 47 trials
• tau: 29 trials
• tauro: 29 trials
• amyloid: 14 trials
• neurotransmitter: 7 trials
• metabolic: 4 trials
• synaptic: 4 trials

Investment Context

Frontotemporal dementia represents an underserved area with only 380 total clinical trials. The small pipeline (12 Phase 3 trials) reflects diagnostic challenges and heterogeneity of the disorder. Investment in FTD remains significantly below Alzheimer's despite similar disease burden.

Key Investment Themes

...

Investment Landscape: Frontotemporal Dementia

Overview

Investment Landscape: Frontotemporal Dementia covers the current R&D investment,
clinical trial pipeline, and funding trends for Frontotemporal Dementia research.

Last updated: 2026-03-22 03:00 PT

Clinical Trial Pipeline

Total Clinical Trials: 380 Active Trials (Recruiting/Active): 124

Trial Phases

| Phase | Count |
|-------|-------|
| PHASE1 | 34 |
| PHASE1, PHASE2 | 12 |
| PHASE2 | 46 |
| PHASE2, PHASE3 | 3 |
| PHASE3 | 12 |
| PHASE4 | 8 |
| NA | 111 |
| Not Applicable | 144 |

Trial Status

| Status | Count |
|--------|-------|
| RECRUITING | 84 |
| ACTIVE_NOT_RECRUITING | 24 |
| NOT_YET_RECRUITING | 16 |
| COMPLETED | 172 |
| TERMINATED | 19 |
| WITHDRAWN | 10 |

Top Therapeutic Approaches

• genetic: 71 trials
• mitochondrial: 47 trials
• tau: 29 trials
• tauro: 29 trials
• amyloid: 14 trials
• neurotransmitter: 7 trials
• metabolic: 4 trials
• synaptic: 4 trials

Investment Context

Frontotemporal dementia represents an underserved area with only 380 total clinical trials. The small pipeline (12 Phase 3 trials) reflects diagnostic challenges and heterogeneity of the disorder. Investment in FTD remains significantly below Alzheimer's despite similar disease burden.

Key Investment Themes

• Tau Targeting: Primary focus on tau pathology given overlap with AD
• TDP-43 Pathology: Emerging area for sporadic FTD
• Genetic Subtypes: Investment in GRN, MAPT, and C9orf72-associated FTD
• Behavioural Interventions: Non-pharmacological approaches for symptom management

Emerging Investment Areas

FTD research is benefiting from advances in tau PET imaging and fluid biomarkers. Progranulin replacement therapies are in development for the significant fraction of FTD cases with GRN mutations. Microglial modulation targeting TREM2 and other microglial receptors offers a novel approach. The overlap with ALS for C9orf72 cases is enabling cross-disease therapeutic development.

Priority Research Gaps

Late-Stage Development Bottleneck

Only 3.2% of trials are in Phase 3, indicating a significant gap between early discovery and late-stage clinical development. Investment in clinical trial infrastructure and regulatory engagement could accelerate late-stage programs.

Recommended Priorities

Phase 2→3 Translation: Enhance predictive biomarkers and clinical endpoints

Trial Design Innovation: Adaptive trials and platform protocols

Patient Recruitment: Investment in trial-ready cohorts and registry infrastructure

Therapeutic Target Priorities

Based on trial count analysis, the following mechanism categories represent either well-invested areas or underserved opportunities:

• genetic: 71 trials - Well-established
• mitochondrial: 47 trials - Growing area
• tau: 29 trials - Growing area
• tauro: 29 trials - Growing area
• amyloid: 14 trials - Growing area

Investment Outlook

Near-Term Opportunities (1-3 Years)

Continued Phase 2/3 readouts expected for leading mechanisms. Focus on biomarker-positive trials for enrichment. Regulatory pathways becoming clearer for disease-modifying therapies.

Medium-Term Opportunities (3-5 Years)

Gene therapies and RNA-targeting modalities expected to expand. Combination therapy trials likely to increase. Patient stratification through genetic and biomarker testing becoming standard.

Long-Term Vision (5-10 Years)

Prevention trials in pre-symptomatic populations. Personalized medicine approaches based on genetic profiles. Disease-modifying therapies potentially becoming standard of care.

Related Pages

• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Tau Pathology](/mechanisms/tau-pathology)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [Clinical Trials: FTD](/clinical-trials)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Unknown, ClinicalTrials.gov (n.d.)